Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Processa Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
PCSA
Nasdaq
2834
https://www.processapharmaceuticals.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Processa Pharmaceuticals Inc
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
- Apr 11th, 2024 12:00 pm
Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k
- Apr 7th, 2024 1:50 pm
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
- Mar 28th, 2024 12:15 pm
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
- Mar 25th, 2024 12:15 pm
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
- Feb 21st, 2024 1:15 pm
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
- Feb 14th, 2024 6:00 pm
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
- Feb 6th, 2024 1:30 pm
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
- Feb 1st, 2024 9:22 pm
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
- Jan 26th, 2024 2:04 pm
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
- Jan 25th, 2024 1:30 pm
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
- Jan 19th, 2024 12:45 pm
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
- Jan 18th, 2024 12:45 pm
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
- Jan 2nd, 2024 10:06 pm
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
- Dec 19th, 2023 2:00 pm
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
- Dec 13th, 2023 2:00 pm
Is Processa Pharmaceuticals (NASDAQ:PCSA) In A Good Position To Invest In Growth?
- Dec 12th, 2023 10:28 am
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
- Nov 30th, 2023 1:15 pm
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
- Nov 29th, 2023 1:15 pm
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
- Nov 13th, 2023 6:40 pm
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
- Nov 9th, 2023 1:15 pm
Scroll